NCT06823609View on ClinicalTrials.gov

Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2027

Conditions

Advanced Malignant Tumor

Interventions

DRUG

QLS1304 tablet

QLS1304 monotherapy dose escalation and expansion

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY